FDA OK's Ipsen's Somatuline in gastrointestinal/pancreatic tumors
This article was originally published in Scrip
Executive Summary
The FDA gave the go-ahead for Ipsen to market Somatuline Depot (lanreotide) injection 120mg as a treatment for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults with unresectable, well or moderately differentiated, locally advanced or metastatic disease to improve progression-free survival (PFS).